The the stock of vaccine maker has fallen by 15.87% in the past month, lagging the Medical sector's gain of 1.74% and the S&P 500's gain of 3.53%. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-a ...

Does it make sense to invest in COVID-19 vaccine stocks in 2024? It should make sense, at least in theory, since U.S. health regulators effectively gave Novavax (NASDAQ:NVAX) the green light to target a specific Covid-19 variant. Yet, it's too late to buy Novavax stock with confidence as meme-stock madness sent the share price to the moon already. I'll bet you never imagined that there would be a connection between GameStop (NYSE:GME) and Novavax. Yet, in these bizarre times, there's actually a link between ...

Core Viewpoint - Novavax has filed a regulatory application with the EMA to update its protein-based COVID-19 vaccine for the 2024/2025 vaccination campaign, aligning with EMA and WHO guidance to target the JN.1 variant [1][2][4]. Company Developments - Novavax's stock has increased by 192.1% year-to-date, contrasting with a 4.1% decline in the industry [3]. - Sanofi will gain global co-marketing rights for Novavax's COVID-19 vaccine starting next year, with Novavax eligible to receive up to $1.2 billion, including $500 million upfront and milestone payments, along with tiered double-digit percentage royalties on sales [6][13]. - The partnership with Sanofi alleviates previous concerns about Novavax's ability to continue as a 'going concern' [7]. Vaccine Efficacy and Market Position - The updated vaccine targets the JN.1 variant but is also effective against currently circulating strains, including KP.2 and KP.3 [8]. - Novavax's COVID-19 vaccine is currently authorized in the EU for individuals aged 12 and older, with a similar filing submitted to the FDA [10]. - Compared to Pfizer and Moderna, Novavax faced challenges during the last vaccination season due to delayed vaccine approval and launch, but early participation in the upcoming season may present new opportunities [12]. Future Plans and Innovations - Novavax is working with global regulatory authorities to secure approvals for the updated vaccine [9]. - The company plans to expand its pipeline using funds from the Sanofi deal, including developing a new approach for H5N1 bird flu vaccination and advancing technology for mucosal vaccination and high-density nanoparticles [14].

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Revisions to Earnings Estimates For the current quarter, Novavax is expected to post earnings of $1.13 per share, indicating a change of +94.8% from the year-ago quarter. The Zacks Consensus Estimate has changed +544.9% over the last 30 days. With an impressive externally audited track record, our prop ...

Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax intends to have its vaccine in unit-dose vials available for distribution in the European Union for immediate release post-approval. Novavax has also filed with the U.S. Food and Drug Administration (FDA) and is working with other regulatory authorities globally on authorization or approval of its JN.1 COVID-19 vaccine. When added to vaccines, Novavax's patented saponin-based Matrix-M adjuvant enha ...

Heading into today, shares of the vaccine maker had lost 12.2% over the past month, lagging the Medical sector's gain of 0.03% and the S&P 500's gain of 3.59% in that time. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Novavax (NVAX) closed the most recent trading d ...

Core Viewpoint - The article discusses the potential for short-squeeze stocks to deliver significant returns, particularly in the context of recent market trends and specific companies that may benefit from positive news and high short interest. Group 1: Short-Squeeze Stocks - Novavax (NVAX) experienced a dramatic increase in stock price from $3.5 to $23.86 following positive news, highlighting the volatility and potential of short-squeeze stocks [1] - The upcoming meme stock frenzy is expected to bring attention back to short-squeeze stocks, where even a single positive development can lead to substantial stock price surges [2] Group 2: EVgo (EVGO) - EVgo has seen a 50% correction in the last year, yet high short interest presents an opportunity for accumulation, supported by positive business catalysts [4] - For Q1 2024, EVgo reported a revenue increase of 118% year-on-year to $55.2 million, with the addition of 250 new operating stalls, indicating strong growth potential [5] - The company reported an EBITDA loss of $7.2 million for Q1 2024, a significant improvement from $20.1 million in Q1 2023, suggesting a trend towards narrowing losses and a path to adjusted EBITDA breakeven by 2025 [6] Group 3: Aurora Cannabis (ACB) - Aurora Cannabis is positioned for a potential breakout rally due to a favorable regulatory environment, including Germany's legalization of cannabis and potential reclassification in the U.S. [7][8] - The company operates in 15 global cannabis markets and has shown healthy growth in its medicinal cannabis business, with expectations for continued strong growth [8] - Aurora has reported positive adjusted EBITDA for five consecutive quarters and reaffirmed guidance for positive free cash flow, enhancing its financial flexibility for future investments [9] Group 4: Beyond Meat (BYND) - Beyond Meat has a high short interest of nearly 40% and has seen a 47% decline in stock price over the past year, reflecting investor concerns about growth [10] - For Q1 2024, Beyond Meat reported an 18% year-on-year revenue decline to $75.6 million, with an adjusted EBITDA loss of $32.9 million, indicating ongoing struggles [11] - The company is working to strengthen its balance sheet and achieve profitability, with new product launches like Beyond IV aimed at revitalizing growth [12]

Subject to necessary permissions from the FDA and CDC, Novavax intends to market this updated COVID-19 vaccine in pre-filled syringes by mid-August. If authorized/approved, it will be the only protein-based nonmRNA COVID-19 vaccine in the United States. The FDA's prior advice was in line with the recommendation issued by a World Health Organization (WHO) advisory committee on Apr 26. However, the FDA pointed out that post the WHO recommendation, another subvariant named KP.2 has become the dominant strain i ...

Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax's JN.1 COVID-19 vaccine would be the only protein-based option available in the U.S. Novavax's filing is aligned with FDA, EMA and WHO global recommendations on vaccine composition Novavax intends to have its vaccine in pre-filled syringes available in the U.S. for immediate release postauthorization and following recommendation by the U.S. CDC Novavax's JN.1 vaccine has demonstrated broad ...

Core Viewpoint - Novavax's stock has significantly outperformed the market, returning +104.6% over the past month compared to the S&P 500's +3.3% [1] Earnings Estimates Revisions - The consensus earnings estimate for Novavax is $0.37 for the current fiscal year, reflecting a year-over-year increase of +106.8% and a change of +144.5% over the last 30 days [2] - For the current quarter, Novavax is expected to report earnings of $1.13 per share, indicating a +94.8% change from the same quarter last year, with the consensus estimate changing by +241.6% in the last 30 days [11] - The consensus earnings estimate for the next fiscal year is $0.42, showing a +15.6% change year-over-year, but has seen a drastic change of -840% over the past month [12] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $429.83 million, indicating a year-over-year change of +1.3% [15] - For the current fiscal year, the sales estimate is $999.14 million, reflecting a +1.6% change, while the next fiscal year's estimate is $553.03 million, indicating a -44.7% change [15] - Last reported revenues were $93.86 million, representing a +16% year-over-year change, with an EPS of -$1.05 compared to -$3.41 a year ago [16] Valuation - Novavax is graded D in terms of valuation, indicating it is trading at a premium compared to its peers [8] - The Zacks Value Style Score system helps assess whether Novavax is overvalued, rightly valued, or temporarily undervalued [18] - The Zacks Rank for Novavax is 3 (Hold), suggesting it may perform in line with the broader market in the near term [3][19] Performance History - Over the last four quarters, Novavax has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [20]